Price$3.30+0.05 (+1.54%)
01:45 PM03:15 PM
News · 26 weeks61+25%
2026-01-182026-07-12
Mix2790d
- SEC Filings13(48%)
- Other10(37%)
- Insider3(11%)
- Analyst1(4%)
Latest news
25 items- SECSEC Form 6-K filed by Can-Fite Biopharma Ltd6-K - Can-Fite BioPharma Ltd. (0001536196) (Filer)
- PRCan-Fite Secures Australian Patent Allowance Supporting Namodenoson Development and Marketing in Liver and Pancreatic CancerRamat Gan, Israel, July 14, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today announced that the Australian Patent Office has allowed Patent Application No. 2021290439 entitled "Treatment of Advanced Metastatic Cancer." The patent complements Can-Fite's rapidly advancing oncology pipeline. Namodenoson is currently being evaluated in a pivotal Phase 3 study for advanced hepatocellular carcinoma following FDA and EMA protocol agreement. In pancreatic cancer, the Company recently completed a Phase 2a clinical study de
- SECSEC Form 6-K filed by Can-Fite Biopharma Ltd6-K - Can-Fite BioPharma Ltd. (0001536196) (Filer)
- PRCan-Fite Achieves Key Pivotal Phase 3 Psoriasis Milestone with Completion of Patient Enrolment for the Interim Analysis: Data Expected Q4 2026/Q1 2027Interim analysis to be conducted under an FDA- and EMA-agreed protocol Ramat Gan, Israel, July 06, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today announced completion of enrolment of the first 247 patients in its pivotal Phase 3 study evaluating Piclidenoson for the treatment of moderate-to-severe plaque psoriasis. The study has now reached the pre-specified interim analysis stage under a protocol agreed with both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). The interim
- SECSEC Form 6-K filed by Can-Fite Biopharma Ltd6-K - Can-Fite BioPharma Ltd. (0001536196) (Filer)
- PRCan-Fite Phase 2a Pancreatic Cancer Study with Namodenoson Achieves Primary Safety Endpoint and Demonstrates Durable Survival Outcomes in Advanced DiseasePredominantly third-line pancreatic cancer patients demonstrated durable survival despite advanced disease; patient who received Namodenoson as second-line therapy remains alive more than 18 months Ramat Gan, Israel, July 01, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today announced that its Phase 2a study evaluating Namodenoson in patients with advanced pancreatic ductal adenocarcinoma achieved its primary safety endpoint and demonstrated durable overall survival outcomes. The open-label Phase IIa study enroll
- SECSEC Form 6-K filed by Can-Fite Biopharma Ltd6-K - Can-Fite BioPharma Ltd. (0001536196) (Filer)
- PRCan-Fite Secures Japanese Patent Allowance for Namodenoson's Anti-Obesity TechnologyThe allowed Patent strengthens protection in one of the world's largest pharmaceutical markets and further supports Namodenoson's positioning in obesity and metabolic diseases Ramat Gan, Israel, June 26, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today announced that the Japan Patent Office has allowed Japanese Patent Application No. 2025-049941, a divisional application of JP 2023-078136, titled "An A3 Adenosine Receptor Ligand for Use for Achieving a Fat Loss Effect." The allowed patent covers the use of A3 ad
- SECSEC Form 6-K filed by Can-Fite Biopharma Ltd6-K - Can-Fite BioPharma Ltd. (0001536196) (Filer)
- PRCan-Fite Publishes Peer-Reviewed Scientific Article Demonstrating the Broad Therapeutic Potential of Piclidenoson and NamodenosonRamat-Gan, Israel, June 22, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced the publication of a peer-reviewed scientific article demonstrating the broad therapeutic potential of its lead drug candidates, Piclidenoson and Namodenoson, across multiple major diseases. "The article, entitled "Adenosine A3 Receptor Agonists as Multisystemic Disease Modifiers: From Molecular Signaling to Clinical Translation" was published in the peer-reviewed Biomolecules Journal (link). The publication reviews findings from Can-Fite w
- SECSEC Form 6-K filed by Can-Fite Biopharma Ltd6-K - Can-Fite BioPharma Ltd. (0001536196) (Filer)
- PRCan-Fite to Present Late-Stage Clinical Pipeline and Licensing Opportunities at BIO International Convention 2026Company to Conduct Partnering Meetings Focused on Oncology, Liver Disease and Inflammatory Disease RAMAT GAN, Israel, June 17, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small-molecule drugs targeting oncological and inflammatory diseases, today announced its participation in the BIO International Convention 2026, to be held June 22–25, 2026, in San Diego, California. BIO International Convention | June 22-25 | San Diego During the conference, Can-Fite will conduct partnering meetings with pharmaceutical companies, biotechnology firms, and potential strategic partners to discuss licensing and comm
- INSIDERSEC Form 4 filed by CEO, CFO and COO Farbstein Motti4 - Can-Fite BioPharma Ltd. (0001536196) (Issuer)
- INSIDERSEC Form 4 filed by Chief Scientific Officer Fishman Pnina4 - Can-Fite BioPharma Ltd. (0001536196) (Issuer)
- SECSEC Form 6-K filed by Can-Fite Biopharma Ltd6-K - Can-Fite BioPharma Ltd. (0001536196) (Filer)
- SECSEC Form 6-K filed by Can-Fite Biopharma Ltd6-K - Can-Fite BioPharma Ltd. (0001536196) (Filer)
- PRCan-Fite Reports Positive Clinical Observation in Phase 2a Pancreatic Cancer Study and Highlights Namodenoson's RAS Signaling Inhibition MechanismGrowing momentum for RAS inhibition at ASCO highlights Namodenoson's RAS pathway inhibition and encouraging data in pancreatic cancer Ramat Gan, Israel, June 02, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs for the treatment of cancer and inflammatory diseases, today highlighted the differentiated mechanism of action of namodenoson in pancreatic cancer, including inhibition of the RAS signaling pathway, alongside encouraging clinical observations from its ongoing Phase 2a pancreatic cancer study. Recent presentations and publications emerging from the 2026 Ameri
- SECSEC Form 6-K filed by Can-Fite Biopharma Ltd6-K - Can-Fite BioPharma Ltd. (0001536196) (Filer)
- SECSEC Form 6-K filed by Can-Fite Biopharma Ltd6-K - Can-Fite BioPharma Ltd. (0001536196) (Filer)
- PRScientific Publication of Can-Fite and Vetbiolix Validates Piclidenoson's Potential in the Multi-Billion Dollar Canine Osteoarthritis MarketRamat Gan, Israel, May 18, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced publication of a peer-reviewed scientific article regarding previously reported positive findings from a study evaluating Piclidenoson for the treatment of canine osteoarthritis. The article abstract, titled "Piclidenoson, an A3 Adenosine Receptor Agonist, Improves Clinical Signs in Dogs with Osteoarthritis" was published in the peer-reviewed journal Frontiers in Veterinary Science and is available online. The study described in the publicat
- ANALYSTCan-Fite BioPharma upgraded by D. Boral Capital with a new price targetD. Boral Capital upgraded Can-Fite BioPharma from Hold to Buy and set a new price target of $7.00
- SECSEC Form 6-K filed by Can-Fite Biopharma Ltd6-K - Can-Fite BioPharma Ltd. (0001536196) (Filer)
- PRFollowing Positive Phase 2a Pancreatic Cancer Data, Can-Fite Advances Namodenoson into Phase 2b Combination Study with ImmunotherapyPhase 2b study design to be discussed at BIO International Convention in San Diego as Can-Fite advances partnership negotiations with leading oncology companies Ramat Gan, Israel, May 13, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE:CANF, TASE: CANF)), a clinical-stage biotechnology company developing oral small molecule drugs targeting the A3 adenosine receptor (A3AR), today announced plans to advance its pancreatic cancer program into a Phase 2b study evaluating Namodenoson in combination with immunotherapy in patients with advanced pancreatic cancer. The planned Phase 2b study follows encouraging findings from the Company's ongoing Phase 2a study evaluating Namodenoson in p
- SECSEC Form 6-K filed by Can-Fite Biopharma Ltd6-K - Can-Fite BioPharma Ltd. (0001536196) (Filer)
- PRCan-Fite Reports Positive Phase 2a Data with Namodenoson in Pancreatic Cancer; 35% of Patients Remain on Therapy, Including One Beyond 16 MonthsRamat Gan, Israel, April 30, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs for the treatment of cancer and inflammatory diseases, today announced positive clinical data from its Phase 2a study of namodenoson in patients with advanced pancreatic cancer. The data from the fully enrolled study demonstrate preliminary evidence of clinical activity, including durable disease stabilization in a heavily pretreated patient population, in addition to the previously reported favorable safety profile. Key findings include: · Stable disease observed in >30% of evaluab
CANF FAQ
6 questionsWhat does Can-Fite Biopharma Ltd do?
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver and inflammatory disease, COVID-19 and erectile dysfunction. The company's lead drug candidate CF101 (Piclidenoson), which is in Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops CF102 (Namodenoson) that is completed Phase II clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase II trial for the treatment of non-alcoholic...Where does CANF stock trade?
Can-Fite Biopharma Ltd (CANF) is listed on AMEX.What sector and industry is CANF in?
Can-Fite Biopharma Ltd operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about CANF?
Can-Fite Biopharma Ltd has had 2 recent analyst actions on file. The most recent action was from D. Boral Capital: Buy with a $700.00 price target on 2026-05-13. Recent price targets range from $500.00 to $700.00.What companies are similar to CANF?
Notable peers in the same industry include RCUS (Arcus Biosciences Inc.), CRVS (Corvus Pharmaceuticals Inc.), ITOS (iTeos Therapeutics Inc.). Compare CANF side-by-side with any of them on Quantisnow.How can I track CANF on Quantisnow?
Quantisnow aggregates Can-Fite Biopharma Ltd's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CANF to receive live email and push alerts on every new disclosure.